Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Prospective Study of Recombinant Human Endostatin Combined with Cytotoxic Chemotherapy Regimen in the Treatment of Recurrent Gliomas

NCT04267978 is registered in ClinicalTrials.gov with Beijing Sanbo Brain Hospital as lead sponsor.

NCT NCT04267978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04267978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Prospective Study of Recombinant Human Endostatin Combined with Cytotoxic Chemotherapy Regimen in the Treatment of Recurrent Gliomas
Lead sponsor
Beijing Sanbo Brain Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
February 13, 2020
Completion date
December 31, 2025
Enrollment
109 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, recurrent, lower grade glioma, recurrent